# A Multiple Dose Opioid Challenge Study

> **NCT02611752** · PHASE2 · COMPLETED · sponsor: **Braeburn Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Moderate or Severe Opioid Use Disorder

## Interventions

- **DRUG:** CAM2038

## Key facts

- **NCT ID:** NCT02611752
- **Lead sponsor:** Braeburn Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611752, "A Multiple Dose Opioid Challenge Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02611752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*